Tags

, , , , ,

Here I discuss the issues related to recuperating an investment in agricultural biotechnologies’ return over time and recuperating such investment with increases in cost of regulatory compliance or delays on the onset of benefits of a potential GM biotechnology. I also discuss the regulatory and knowledge cost/benefit tradeoffs and potential implications especially for public sector research in developing countries.

<div style=”margin-bottom:5px”> <strong> <a href=”https://www.slideshare.net/JoseFalck/falck-zepeda-presentation-abic-2013&#8243; title=”Jose Falck-Zepeda presentation at the 2013 ABIC conference in Calgary Canada” target=”_blank”>Jose Falck-Zepeda presentation at the 2013 ABIC conference in Calgary Canada</a> </strong> from <strong><a href=”http://www.slideshare.net/JoseFalck&#8221; target=”_blank”>Jose Falck Zepeda</a></strong> </div>

Advertisements